Biomerica (NASDAQ:BMRA) Shares Pass Below 200 Day Moving Average – What’s Next?

Shares of Biomerica, Inc. (NASDAQ:BMRA) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.81 and traded as low as $2.33. Biomerica shares last traded at $2.39, with a volume of 15,858 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biomerica in a research report on Tuesday, October 14th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Biomerica currently has a consensus rating of “Sell”.

Biomerica Stock Performance

The company has a market capitalization of $7.19 million, a price-to-earnings ratio of -2.56 and a beta of 0.11. The business’s 50 day moving average price is $2.50 and its two-hundred day moving average price is $2.81.

Biomerica (NASDAQ:BMRA) last issued its quarterly earnings results on Wednesday, January 14th. The company reported ($0.45) EPS for the quarter. The firm had revenue of $1.21 million during the quarter. Biomerica had a negative net margin of 90.29% and a negative return on equity of 83.73%.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.